Document:

EX-10.23

 Exhibit 10.23 

Execution Version 

CONTRIBUTION, ASSIGNMENT AND ASSUMPTION AGREEMENT 

THIS CONTRIBUTION, ASSIGNMENT AND ASSUMPTION AGREEMENT (this “Agreement”) is made on September 28, 2021 (the
“Agreement Execution Date”) and effective as of August 10, 2020 (the “Agreement Effective Date”) by and among LianBio Licensing, LLC, a limited liability company organized and existing under the laws of
Delaware, United States (“LianBio Licensing”), Lian Cardiovascular, an exempted company organized under the laws of the Cayman Islands (“Lian Cardiovascular”) and LianBio, an exempted company organized under the
laws of the Cayman Islands (“LianBio”). Each of LianBio Licensing, Lian Cardiovascular and LianBio is referred to herein as a “Party” and, collectively, as the “Parties”. 

INTRODUCTION 

WHEREAS, LianBio Licensing, LianBio and MyoKardia, Inc. (“MyoKardia”) are parties to a certain Exclusive License Agreement
dated August 10, 2020 (the “License Agreement”), attached hereto as Exhibit A, pursuant to which LianBio Licensing (as Licensee) acquired from MyoKardia (as Company) certain rights and licenses under certain intellectual
property owned or controlled by MyoKardia to Develop, Manufacture and Commercialize Licensed Products in the Field in the Territory (each as defined in the License Agreement), all upon the terms and subject to the conditions set forth in the License
Agreement (the “MyoKardia IP” or Licensed Rights”); 
 WHEREAS, (A) LianBio Licensing desires to
assign and transfer, and effect an assignment of, the License Agreement to Lian Cardiovascular, including all of LianBio Licensing’s rights and obligations thereunder, such that Lian Cardiovascular assumes all of LianBio Licensing’s rights
and obligations thereunder as if the original party thereto in place of LianBio Licensing, (B) Lian Cardiovascular desires to accept and agree to such assignment, and (C) LianBio desires to consent and agree to such assignment; 

WHEREAS, at the time of the License Agreement, LianBio intended for all of LianBio Licensing’s rights and obligations under the License
Agreement, including the Licensed Rights, to benefit Lian Cardiovascular, and that it was the intent of LianBio and LianBio Licensing that Lian Cardiovascular own the beneficial interests in the Licensed Rights; and 

WHEREAS, all payments made by LianBio Licensing to MyoKardia under the License Agreement prior to the Agreement Execution Date (the
“MyoKardia Payments”) were contributions by LianBio to Lian Cardiovascular in consideration for and in respect of LianBio’s equity interests in Lian Cardiovascular, and that such payments were made on behalf of and at the
direction of Lian Cardiovascular. 
 NOW, THEREFORE, in consideration of the mutual covenants contained herein, the Parties hereto agree as
follows: 
  

	1.	 Assignment and Assumption. 

 

	 	1.1.	 Effective as of the Agreement Effective Date, LianBio Licensing hereby irrevocably assigns and transfers to
Lian Cardiovascular all rights, licenses, title, interest, claims, demands, liabilities, duties, and obligations of LianBio Licensing under the License Agreement, including, without limitation, the Licensed Rights and all rights, interests,

	 	
claims, and demands recoverable in law or equity that LianBio Licensing has or may have under the License Agreement (a) for past, present and future infringements of the MyoKardia IP,
(b) for past, present, and future breaches by MyoKardia of the License Agreement, (c) for past, present, and future tort or fraud claims, and (d) for compromising, settling, suing for, and collecting any profits and damages in
connection with any of the foregoing, all of the foregoing to be held and enjoyed by Lian Cardiovascular, its successors and assigns or their legal representatives, as fully and entirely as if Lian Cardiovascular had at all times been a party to the
License Agreement in place of LianBio Licensing (such assignment, the “Assignment”). 

  

	 	1.2.	 Lian Cardiovascular hereby (a) irrevocably accepts the Assignment, and (b) (i) agrees to be bound by
the License Agreement in accordance with its terms, (ii) assumes all liabilities, duties, and obligations of LianBio Licensing under the License Agreement, and (iii) acquires all rights, licenses, title, interest, claims, and demands of
LianBio Licensing under the License Agreement, including, without limitation, the Licensed Rights, in each case, as if Lian Cardiovascular had at all times been a party to the License Agreement in place of LianBio Licensing. 

 

	 	1.3.	 Lian Cardiovascular shall assume all liability for any breach,
non-observance or failure by LianBio Licensing to perform any performance, covenants, agreements, duties, and obligations expressed to be undertaken by LianBio Licensing under the License Agreement,
irrespective of whether or not any such breach, non-observance or failure is known to any of the Parties. 

  

	2.	 Contribution and Direction for Payment. The Parties acknowledge and agree that the MyoKardia Payments
were made on behalf of, and at the direction of, Lian Cardiovascular, and any such payments are treated by the Parties as a contribution to Lian Cardiovascular in exchange for, and in respect of, LianBio’s equity interest in Lian
Cardiovascular. 

  

	3.	 Release. All actions prior to the Agreement Execution Date taken by LianBio Licensing in fulfillment of
its obligations and duties under the License Agreement shall be considered to have discharged those parts of LianBio Licensing’s obligations and duties under the License Agreement. All payments, obligations and duties of LianBio Licensing under
the License Agreement due and payable or due to be performed on or prior to the Agreement Execution Date shall be paid or performed by Lian Cardiovascular in accordance with the terms of the License Agreement. 

 

	4.	 Consent and Agreement of LianBio. LianBio hereby irrevocably consents and agrees to the Assignment,
assumption, contribution and release described in Section 1, Section 2 and Section 3 above. 

 

	5.	 Further Assurances. Each Party shall duly execute and deliver or cause to be duly executed and
delivered, such further instruments and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents and instruments, as may be necessary or as the other Party may reasonably request to effect
the intent and purposes of this Agreement. 

  

	6.	 Interpretation; Successors. It is the clear intent of all Parties that the Assignment will be
interpreted as an assignment and not a novation. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the License Agreement. This Agreement shall be binding upon and inure solely to the benefit of the Parties and
their respective successors and permitted assigns, and shall not be construed as conferring any rights on any other person. 

	7.	 Governing Law. Construction and interpretation of this Agreement shall be governed by the laws of the
State of New York, excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. 

 

	8.	 Dispute Resolution. 

 

	 	8.1.	 Dispute Resolution; Escalation. The Parties recognize that disputes as to certain matters arising out of
or in connection with this Agreement may arise from time to time. It is the objective of the Parties to establish procedures to facilitate the resolution of disputes arising out of or in connection with this Agreement in an expedited manner by
mutual cooperation. To accomplish this objective, the Parties will first attempt to resolve any and all disputes amongst the Parties arising out of or in connection with this Agreement through good faith discussions. Should the Parties not be able
to reach agreement within fifteen (15) days after the date on which the Parties commenced discussions, then any Party may refer such matter to the Chief Executive Officers of each Party for resolution and the Chief Executive Officers of each
Party will attempt to resolve the matter in good faith. If the Chief Executive Officers of each Party fail to resolve such matter within fifteen (15) Business Days after the date on which the matter is first referred to the Chief Executive
Officers of each Party (unless a longer period is agreed to by the Parties), then, any Party may submit the dispute for final resolution by binding arbitration in accordance with Section 8.2. 

 

	 	8.2.	 Arbitration. Except as set forth in this Section 8.2, each dispute,
difference, controversy or claim arising in connection with or related or incidental to, or question occurring under, this Agreement or the subject matter hereof that cannot be resolved pursuant to Section 8.1 will be
referred to and finally resolved by arbitration in accordance with the International Chamber of Commerce Rules (the “Rules”) by an arbitral tribunal composed of three (3) arbitrators, all of whom will have previous judicial
experience and significant experience in the pharmaceutical industry, with the two (2) initial arbitrators appointed in accordance with the Rules and the third arbitrator to be selected by mutual agreement of the two (2) initial
arbitrators. If the two (2) initial arbitrators are unable to select a third arbitrator within thirty (30) days, the third arbitrator will be appointed in accordance with the Rules. The foregoing arbitration proceedings may be commenced by
any Party by notice to the other Parties. Unless otherwise agreed by the Parties, all such arbitration proceedings will be held in New York, New York, USA; provided, however, that proceedings may be conducted by telephone
conference call with the consent of the Parties and the arbitrator(s). All arbitration proceedings will be conducted in the English language. The arbitrators will consider grants of equitable relief and orders for specific performance as co-equal remedies along with awards of monetary damages. The arbitrators will have no authority to award punitive damages. The allocation of expenses of the arbitration, including reasonable attorney’s fees,
will be determined by the arbitrators, or, in the absence of such determination, each Party will pay its own expenses. The Parties hereby agree that the arbitrators have authority to issue rulings and orders regarding all procedural and evidentiary
matters that the arbitrators deem reasonable and necessary with or without petition therefore by the Parties as well as the final ruling and judgment. All rulings by the arbitrators will be final. Notwithstanding

	 	
any contrary provision of this Agreement, any Party may seek equitable measures of protection in the form of attachment of assets or injunctive relief (including specific performance and
injunctive relief) in any matter relating to the proprietary rights and interests of any Party from any court of competent jurisdiction, pending a decision by the arbitral tribunal in accordance with this Section 8.2). The
Parties hereby exclude any right of appeal to any court on the merits of such matter. The provisions of this Section 8.2 may be enforced and judgment on the award (including equitable remedies) granted in any arbitration
hereunder may be entered in any court having jurisdiction over the award or any of the Parties or any of their respective assets. Except to the extent necessary to confirm an award or as may be required by laws, neither a Party nor an arbitrator may
disclose the existence, content, or results of an arbitration without the prior written consent of all Parties. The Parties agree that, in the event of a dispute over the nature or quality of performance under this Agreement, no Party may terminate
this Agreement until final resolution of the dispute through arbitration or other judicial determination. Nothing in this Section 8.2 will preclude any Party from seeking interim or provisional relief from a court of
competent jurisdiction, including a temporary restraining order, preliminary injunction or other interim equitable relief, concerning a dispute either prior to or during any arbitration if necessary to protect the interests of such Party or to
preserve the status quo pending the arbitration proceeding. 

  

	 	8.3.	 Jury Waiver. EACH PARTY, TO THE EXTENT PERMITTED BY LAW, KNOWINGLY, VOLUNTARILY, AND INTENTIONALLY
WAIVES ITS RIGHT TO A TRIAL BY JURY IN ANY ACTION OR OTHER LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT AND THE TRANSACTIONS IT CONTEMPLATES TO ARBITRATE AS SET FORTH IN SECTION 8.2. THIS WAIVER APPLIES TO ANY ACTION OR LEGAL
PROCEEDING, WHETHER SOUNDING IN CONTRACT, TORT OR OTHERWISE. 

  

	9.	 Counterparts. This Agreement may be executed in counterparts, each of which counterparts, when so
executed and delivered, will be deemed to be an original, and all of which counterparts, taken together, will constitute one and the same instrument even if all Parties have not executed the same counterpart. Signatures provided by facsimile
transmission or in AdobeTM Portable Document Format (PDF) sent by electronic mail will be deemed to be original signatures. 

[Remainder of Page Intentionally Left Blank.] 

 IN WITNESS WHEREOF, each Party has caused this Agreement to be duly executed by its authorized
representative on the Agreement Execution Date. 
  

			
	LIANBIO LICENSING, LLC
		
	By:	 	 /s/ Yizhe Wang

		 	Name: Yizhe Wang
		 	Title:   Manager

 [Signature Page to Contribution, Assignment and Assumption Agreement] 

 IN WITNESS WHEREOF, each Party has caused this Agreement to be duly executed by its authorized
representative on the Agreement Execution Date. 
  

			
	LIANBIO
		
	By:	 	 /s/ Yizhe Wang

		 	Name: Yizhe Wang
		 	Title:   Director

 [Signature Page to Contribution, Assignment and Assumption Agreement] 

 IN WITNESS WHEREOF, each Party has caused this Agreement to be duly executed by its authorized
representative on the Agreement Execution Date. 
  

			
	LIAN CARDIOVASCULAR
		
	By:	 	 /s/ Yizhe Wang

		 	Name: Yizhe Wang
		 	Title:   Director

 [Signature Page to Contribution, Assignment and Assumption Agreement] 

 Exhibit A 

License Agreement 
 [Exhibit A
to Contribution, Assignment and Assumption Agreement]EX-10.24

 Exhibit 10.24 

Execution Version 

CONTRIBUTION, ASSIGNMENT AND ASSUMPTION AGREEMENT 

THIS CONTRIBUTION, ASSIGNMENT AND ASSUMPTION AGREEMENT (this “Agreement”) is made on September 28, 2021 (the
“Agreement Execution Date”) and effective as of January 1, 2021 (the “Agreement Effective Date”) by and among Lian Cardiovascular, an exempted company organized under the laws of the Cayman Islands
(“Lian Cardiovascular”), Lian Cardiovascular Limited, a private company limited by shares organized under the laws of Hong Kong (“Lian Cardiovascular HK”) and LianBio, an exempted company organized under the laws of
the Cayman Islands (“LianBio”). Each of Lian Cardiovascular, Lian Cardiovascular HK and LianBio is referred to herein as a “Party” and, collectively, as the “Parties”. 

INTRODUCTION 

WHEREAS, LianBio Licensing, LLC, a limited liability company organized and existing under the laws of Delaware, United States
(“LianBio Licensing”), LianBio and MyoKardia, Inc. (“MyoKardia”) are parties to a certain Exclusive License Agreement dated August 10, 2020 (the “License Agreement”), attached hereto as
Exhibit A, pursuant to which LianBio Licensing (as Licensee) acquired from MyoKardia (as Company) certain rights and licenses under certain intellectual property owned or controlled by MyoKardia to Develop, Manufacture and Commercialize
Licensed Products in the Field in the Territory (each as defined in the License Agreement), all upon the terms and subject to the conditions set forth in the License Agreement (the “MyoKardia IP” or Licensed
Rights”); 
 WHEREAS, LianBio Licensing, Lian Cardiovascular and LianBio are parties to a certain Contribution, Assignment and
Assumption Agreement dated September    , 2021 (the “Assignment Agreement”), attached hereto as Exhibit B, pursuant to which LianBio Licensing assigned and transferred the License Agreement to Lian
Cardiovascular and Lian Cardiovascular accepted and agreed to such assignment, all upon the terms and subject to the conditions set forth in the Assignment Agreement; 

WHEREAS, as a contribution by Lian Cardiovascular to Lian Cardiovascular HK in consideration for and in respect of Lian Cardiovascular’s
equity interests in Lian Cardiovascular HK, (A) Lian Cardiovascular desires to assign and transfer, and effect an assignment of, the License Agreement to Lian Cardiovascular HK, including all of Lian Cardiovascular’s rights and obligations
thereunder, such that Lian Cardiovascular HK assumes all of Lian Cardiovascular’s rights and obligations thereunder as if the original party thereto in place of Lian Cardiovascular (as assignee of LianBio Licensing under the Assignment
Agreement), (B) Lian Cardiovascular HK desires to accept and agree to such assignment, and (C) LianBio desires to consent and agree to such assignment; and 

WHEREAS, Lian Cardiovascular intended for all of Lian Cardiovascular’s rights and obligations under the License Agreement (as assignee of
LianBio Licensing under the Assignment Agreement), including the Licensed Rights, to benefit Lian Cardiovascular HK, and that it was the intent of LianBio and Lian Cardiovascular that Lian Cardiovascular HK own the beneficial interests in the
Licensed Rights. 
 NOW, THEREFORE, in consideration of the mutual covenants contained herein, the Parties hereto agree as follows: 

 

	1.	 Assignment and Assumption. 

	 	1.1.	 Effective as of the Agreement Effective Date, Lian Cardiovascular hereby irrevocably assigns and transfers to
Lian Cardiovascular HK all rights, licenses, title, interest, claims, demands, liabilities, duties, and obligations of Lian Cardiovascular under the License Agreement (as assignee of LianBio Licensing under the Assignment Agreement), including,
without limitation, the Licensed Rights and all rights, interests, claims, and demands recoverable in law or equity that Lian Cardiovascular has or may have under the License Agreement (as assignee of LianBio Licensing under the Assignment
Agreement) (a) for past, present and future infringements of the MyoKardia IP, (b) for past, present, and future breaches by MyoKardia of the License Agreement, (c) for past, present, and future tort or fraud claims, and (d) for
compromising, settling, suing for, and collecting any profits and damages in connection with any of the foregoing, all of the foregoing to be held and enjoyed by Lian Cardiovascular HK, its successors and assigns or their legal representatives, as
fully and entirely as if Lian Cardiovascular HK had at all times been a party to the License Agreement in place of Lian Cardiovascular (as assignee of LianBio Licensing under the Assignment Agreement) (such assignment, the
“Assignment”). 

  

	 	1.2.	 Lian Cardiovascular HK hereby (a) irrevocably accepts the Assignment, and (b) (i) agrees to be bound
by the License Agreement in accordance with its terms, (ii) assumes all liabilities, duties, and obligations of Lian Cardiovascular under the License Agreement (as assignee of LianBio Licensing under the Assignment Agreement), and
(iii) acquires all rights, licenses, title, interest, claims, and demands of Lian Cardiovascular under the License Agreement (as assignee of LianBio Licensing under the Assignment Agreement), including, without limitation, the Licensed Rights,
in each case, as if Lian Cardiovascular HK had at all times been a party to the License Agreement in place of Lian Cardiovascular (as assignee of LianBio Licensing under the Assignment Agreement). 

 

	 	1.3.	 Lian Cardiovascular HK shall assume all liability for any breach,
non-observance or failure by Lian Cardiovascular to perform any performance, covenants, agreements, duties, and obligations expressed to be undertaken by Lian Cardiovascular under the License Agreement (as
assignee of LianBio Licensing under the Assignment Agreement), irrespective of whether or not any such breach, non-observance or failure is known to any of the Parties. 

 

	2.	 Contribution. The Parties acknowledge and agree that the Assignment and assumption described in
Section 1 was a contribution by Lian Cardiovascular to Lian Cardiovascular HK in exchange for, and in respect of, Lian Cardiovascular’s equity interest in Lian Cardiovascular HK. 

 

	3.	 Release. All actions prior to the Agreement Execution Date taken by Lian Cardiovascular in fulfillment
of its obligations and duties under the License Agreement shall be considered to have discharged those parts of Lian Cardiovascular’s obligations and duties under the License Agreement (as assignee of LianBio Licensing under the Assignment
Agreement). All payments, obligations and duties of Lian Cardiovascular under the License Agreement (as assignee of LianBio Licensing under the Assignment Agreement) due and payable or due to be performed on or prior to the Agreement Execution Date
shall be paid or performed by Lian Cardiovascular HK in accordance with the terms of the License Agreement. 

  

	4.	 Consent and Agreement of LianBio. LianBio hereby irrevocably consents and agrees to the Assignment,
assumption, contribution and release described in Section 1, Section 2 and Section 3 above. 

	5.	 Further Assurances. Each Party shall duly execute and deliver or cause to be duly executed and
delivered, such further instruments and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents and instruments, as may be necessary or as the other Party may reasonably request to effect
the intent and purposes of this Agreement. 

  

	6.	 Interpretation; Successors. It is the clear intent of all Parties that the Assignment will be
interpreted as an assignment and not a novation. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the License Agreement. This Agreement shall be binding upon and inure solely to the benefit of the Parties and
their respective successors and permitted assigns, and shall not be construed as conferring any rights on any other person. 

  

	7.	 Governing Law. Construction and interpretation of this Agreement shall be governed by the laws of the
State of New York, excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. 

 

	8.	 Dispute Resolution. 

 

	 	8.1.	 Dispute Resolution; Escalation. The Parties recognize that disputes as to certain matters arising out of
or in connection with this Agreement may arise from time to time. It is the objective of the Parties to establish procedures to facilitate the resolution of disputes arising out of or in connection with this Agreement in an expedited manner by
mutual cooperation. To accomplish this objective, the Parties will first attempt to resolve any and all disputes amongst the Parties arising out of or in connection with this Agreement through good faith discussions. Should the Parties not be able
to reach agreement within fifteen (15) days after the date on which the Parties commenced discussions, then any Party may refer such matter to the Chief Executive Officers of each Party for resolution and the Chief Executive Officers of each
Party will attempt to resolve the matter in good faith. If the Chief Executive Officers of each Party fail to resolve such matter within fifteen (15) Business Days after the date on which the matter is first referred to the Chief Executive
Officers of each Party (unless a longer period is agreed to by the Parties), then, any Party may submit the dispute for final resolution by binding arbitration in accordance with Section 8.2. 

 

	 	8.2.	 Arbitration. Except as set forth in this Section 8.2, each dispute,
difference, controversy or claim arising in connection with or related or incidental to, or question occurring under, this Agreement or the subject matter hereof that cannot be resolved pursuant to Section 8.1 will be
referred to and finally resolved by arbitration in accordance with the International Chamber of Commerce Rules (the “Rules”) by an arbitral tribunal composed of three (3) arbitrators, all of whom will have previous judicial
experience and significant experience in the pharmaceutical industry, with the two (2) initial arbitrators appointed in accordance with the Rules and the third arbitrator to be selected by mutual agreement of the two (2) initial
arbitrators. If the two (2) initial arbitrators are unable to select a third arbitrator within thirty (30) days, the third arbitrator will be appointed in accordance with the Rules. The foregoing arbitration proceedings may be commenced by
any Party by notice to the other Parties. Unless otherwise agreed by the Parties, all such arbitration proceedings will be held in New York, New York, USA; provided, however, that proceedings may be conducted by telephone
conference call with the consent of the Parties and the arbitrator(s). All arbitration proceedings will be conducted in the English 

	 	
language. The arbitrators will consider grants of equitable relief and orders for specific performance as co-equal remedies along with awards of monetary
damages. The arbitrators will have no authority to award punitive damages. The allocation of expenses of the arbitration, including reasonable attorney’s fees, will be determined by the arbitrators, or, in the absence of such determination,
each Party will pay its own expenses. The Parties hereby agree that the arbitrators have authority to issue rulings and orders regarding all procedural and evidentiary matters that the arbitrators deem reasonable and necessary with or without
petition therefore by the Parties as well as the final ruling and judgment. All rulings by the arbitrators will be final. Notwithstanding any contrary provision of this Agreement, any Party may seek equitable measures of protection in the form of
attachment of assets or injunctive relief (including specific performance and injunctive relief) in any matter relating to the proprietary rights and interests of any Party from any court of competent jurisdiction, pending a decision by the arbitral
tribunal in accordance with this Section 8.2). The Parties hereby exclude any right of appeal to any court on the merits of such matter. The provisions of this Section 8.2 may be enforced and
judgment on the award (including equitable remedies) granted in any arbitration hereunder may be entered in any court having jurisdiction over the award or any of the Parties or any of their respective assets. Except to the extent necessary to
confirm an award or as may be required by laws, neither a Party nor an arbitrator may disclose the existence, content, or results of an arbitration without the prior written consent of all Parties. The Parties agree that, in the event of a dispute
over the nature or quality of performance under this Agreement, no Party may terminate this Agreement until final resolution of the dispute through arbitration or other judicial determination. Nothing in this Section 8.2
will preclude any Party from seeking interim or provisional relief from a court of competent jurisdiction, including a temporary restraining order, preliminary injunction or other interim equitable relief, concerning a dispute either prior to or
during any arbitration if necessary to protect the interests of such Party or to preserve the status quo pending the arbitration proceeding. 

  

	 	8.3.	 Jury Waiver. EACH PARTY, TO THE EXTENT PERMITTED BY LAW, KNOWINGLY, VOLUNTARILY, AND INTENTIONALLY
WAIVES ITS RIGHT TO A TRIAL BY JURY IN ANY ACTION OR OTHER LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT AND THE TRANSACTIONS IT CONTEMPLATES TO ARBITRATE AS SET FORTH IN SECTION 8.2. THIS WAIVER APPLIES TO ANY ACTION OR LEGAL
PROCEEDING, WHETHER SOUNDING IN CONTRACT, TORT OR OTHERWISE. 

  

	9.	 Counterparts. This Agreement may be executed in counterparts, each of which counterparts, when so
executed and delivered, will be deemed to be an original, and all of which counterparts, taken together, will constitute one and the same instrument even if all Parties have not executed the same counterpart. Signatures provided by facsimile
transmission or in AdobeTM Portable Document Format (PDF) sent by electronic mail will be deemed to be original signatures. 

[Remainder of Page Intentionally Left Blank.] 

 IN WITNESS WHEREOF, each Party has caused this Agreement to be duly executed by its authorized
representative on the Agreement Execution Date. 
  

			
	LIAN CARDIOVASCULAR LIMITED
		
	By:	 	 /s/ Yizhe Wang

		 	 Name: Yizhe Wang

		 	Title:   Director

 [Signature Page to Contribution, Assignment and Assumption Agreement] 

 IN WITNESS WHEREOF, each Party has caused this Agreement to be duly executed by its authorized
representative on the Agreement Execution Date. 
  

			
	LIANBIO
		
	By:	 	 /s/ Yizhe Wang

		 	 Name: Yizhe Wang

		 	Title:   Director

 [Signature Page to Contribution, Assignment and Assumption Agreement] 

 IN WITNESS WHEREOF, each Party has caused this Agreement to be duly executed by its authorized
representative on the Agreement Execution Date. 
  

			
	LIAN CARDIOVASCULAR
		
	By:	 	 /s/ Yizhe Wang

		 	 Name: Yizhe Wang

		 	Title:   Director

 [Signature Page to Contribution, Assignment and Assumption Agreement] 

 Exhibit A 

License Agreement 
 [Exhibit A
to Contribution, Assignment and Assumption Agreement] 

 Exhibit B 

Assignment Agreement 
 [Exhibit
B to Contribution, Assignment and Assumption Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}]]